Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics 2016
This Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms, antibiotics and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of June 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms, antibiotics and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) C. Difficile Vaccines
2) C. Difficile Therapeutics:
Antibodies
Microbiome-based
Anti-Infective Peptides
Antibiotics
Others
3) Corporate C. Difficile Vaccines & Therapeutics R&D Pipeline
2) C. Difficile Therapeutics:
Antibodies
Microbiome-based
Anti-Infective Peptides
Antibiotics
Others
3) Corporate C. Difficile Vaccines & Therapeutics R&D Pipeline
More Publications
Competitor Analysis: Ebola Virus Vaccines and Therapeutics
US$ 255.00
October 2014
43 pages
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
US$ 394.00
May 2012
46 pages
Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals
US$ 220.00
February 2016
42 pages
Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins
US$ 255.00
September 2014
33 pages
Competitor Analysis: P. aeruginosa Vaccines and Therapeutics
US$ 230.00
June 2010
22 pages
